Eyal Mishani, Monday, November 04, 2013
-1-
CURRICULUM VITAE
Eyal Mishani
Date of Birth – 10/08/63
Work – 972-2-6777931
Email- eyalmi@ekmd.huji.ac.il
1. Appointments at the Hebrew University
1996-2002
Medical Faculty
Nuclear Medicine
Lecturer
2003-2006
Medical Faculty
Nuclear Medicine
Senior Lecturer (with tenure)
2007- 2012
Medical Faculty
Nuclear Medicine
Associate Professor
2012-
Medical Faculty
Nuclear Medicine
Professor
2. Additional function
1996- 2008
Hadassah Hospital
Nuclear Medicine
In charge of the
cyclotron radiochemistry
facility
2008-
Hadassah Hospital
Nuclear Medicine
Director of the
cyclotron radiochemistry
facility
2012-
IAEA
Nuclear Medicine
Expert
3. Board of directors & editorial boards
2005 -
Editorial board member of Nuclear Medicine & Biology, official journal of the
Society of Radiopharmaceutical Sciences.
2008-
International associate editor of Molecular Imaging & Biology Journal.
2011- 2013
Director-at-Large of the Society of Radiopharmaceutical Sciences (SRS) board
of directors.
2012
Nominating Committee for next election of the SRS Officers and Board members.
Society of Radiopharmaceutical Sciences (SRS).
2012-
Review articles subcommittee. Molecular Imaging & Biology Journal.
2013-
Board member of the Society of Radiopharmaceutical Sciences (SRS).
Eyal Mishani, Monday, November 04, 2013
-2-
4. International conferences
2006
Member of the scientific committee, World Congress of Nuclear Medicine
and Biology (WCNMB). Seoul, Korea.
2010
Category organizer & co-chairman, PET/SPECT probes. World Molecular
Imaging Conference. (2 oral sessions and 2 poster sessions about 105
abstracts in this category); Kyoto, Japan.
2011
Category organizer & co-chairman, PET/SPECT probes. World Molecular
Imaging Conference. (2 oral sessions and 2 poster sessions about 130
abstracts in this category) San-Diego, USA.
5. Visiting scientists and seminars organized.
1.
PET Radiopharmaceuticals, Prof. M. J. Welch, Washintgton University.
Hadassah Hebrew University Hospital, November 1997.
2.
Targetry and in target chemistry, Nuclear Research Center Negev, and prof. F.
Helus.
Hadassah Hebrew University hospital, May 1998.
3.
A. The development of receptor radioligands for brain, heart and lung.
B. Protein synthesis in tumor tissue quantified by PET.
C. Molecular biology and PET
Prof. W. Vaalburg, Groningen university hospital.
Hadassah Hebrew University Hospital, August 1999.
4.
Micro-PET, Prof. M. J. Welch, Washintgton University.
Hadassah Hebrew University Hospital, November 2004.
5.
A.Clinical use of 18FDOPA & 11C Choline, Prof. Fanti, University of Bologna.
B. Erbitux and other TK inhibitors in targeted therapy of Colon Carcinoma, Dr.
Pantaleo, Policlinico S. Orsola-Malpighi Hospital.
Hadassah Hebrew University Hospital, April 2006.
6.
New trends in cardiac imaging. Prof. William Strauss, Memorial Slon-Kettering,
USA. Hadassah Hebrew University Hospital, Cyclotron Unit, February 2013.
7.
Brain trauma and dementia: Imaging Tau pathology in living subjects. Prof. J.
Barrio, David Geffen UCLA School of medicine. Israeli society of nuclear
medicine conference, February 2013.
Eyal Mishani, Monday, November 04, 2013
8.
-3-
Monoamines and the brain at work: From experimental design to Clinical studies.
Prof. D. Doudet, University of British Columbia, Canada. Israeli society of nuclear
medicine conference, February 2013.
6. Grants.
1999
Magnet with Teva, A new MAO-B inhibitor-anti Parkinson drug; Use of
PET for in-vivo measurement of Human Monoamine Oxidase B. E.
Mishani, R. Chisin.
1999
International Atomic Energy Agency Grant, National and regional
production of fluorinated radiopharmaceuticals – clinical and scientific
aspects. R. Chisin, E. Mishani.
1999-2002
Binational Science Foundation (BSF), Labeled PET tracers for EGFr-TK
and estrogen receptors. E. Mishani (PI).
2001-2002
Israel Cancer Association, Evaluation of prostate cancer with PET using
[C-11]choline. M. Bocher, E. Mishani, R. Chisin.
2001-2007
A start-up company was established for research on EGFR, HadassahHebrew University -Naiot. (with Prof. A. Levitzki)
2003-2007
NIH, Functional dopamine neurons from human ES cells.
Reubinoff Benjamin (PI), Ben Hur Tamir (Co-Investigator), Bergman Hagi
(Co-Investigator), Mishani Eyal (Co-Investigator), Segal Menahem (CoInvestigator).
2005-2008
Joint German-Israeli Research Program, Development and clinical
application of a PET-SERT ligand labeled with fluorine-18. Eyal Mishani
(PI), Roland Chisin (Co-PI) Joerge Stainbach (Co-PI).
2007-2008
Aposense Inc.- Development the labeling and purification of ML-10, A
potential PET imaging agent for apoptosis. Eyal Mishani (PI).
2007-2010
Israel Science Foundation (ISF), Targeting the Vascular Endothelial
Growth Factor Receptor 2 (VEGFR-2) in cancer - Development of PET
molecular imaging agents. Eyal Mishani (PI).
2008-2010
Pain Therapeutics Inc.- Labeling development (Tc-99m and Re-188),
purification and evaluation, in melanoma mice model, of novel melanin
selective IgGs. Eyal Mishani (PI).
Eyal Mishani, Monday, November 04, 2013
-4-
2010-2011
TEVA Inc. – Development the radiolabeling of Laquinimod, a novel drug
for the treatment of Multiple-Sclerosis, and investigation of Laquinimod’s
distribution in healthy and diseased mice by micro-PET/CT. Eyal Mishani
(PI) and Galith Abourbeh (Co-PI).
2011-2011
Aposense Inc. - F-18 ML10 Micro-PET studies in apoptotic animal model.
Galith Abourbeh (PI), Eyal Mishani (Co-PI).
2011-2014
Israel Science Foundation (ISF), Carbon-11/Fluorine-18 labeled
ammonium salts as myocardial perfusion PET imaging agents. Eyal
Mishani (PI), Galith Abourbeh, Haim Danenberg, Moshe Bocher.
7. Publications
Papers in peer-review journals, original research papers.
1.
S. Rozen, E. Mishani and M. Kol (1991). A novel electrophilic methoxylation (with a
little help from F2). J. Am. Chem. Soc. 114: 7643-7645.
2.
E. Appelman , D. French, E. Mishani and S. Rozen (1993). Synthesis, characterization,
and reaction chemistry of tert-butyl hypofluorite. J. Am. Chem. Soc. 115: 1379-1382.
3.
S. Rozen, E. Mishani (1993). Conversion of esters to -difluoro ethers using BrF3. J.
Chem. Soc. Chem. Commun. 1761-2.
4.
S. Rozen, A. Bar Haim and E. Mishani (1994). A new efficient route to  nitro acids.
oxidation of amino acids with HOF.CH3CN. J. Org. Chem. 59: 1208-9.
5.
S. Rozen, E. Mishani, I. Ben-David and M. Kol (1994). The chemistry of methyl
hypofluorite with various unsaturated centers. J. Org. Chem. 59: 4281-4284.
6.
S. Rozen, E. Mishani, A. Bar-Haim (1994). A novel carbonyl to CF2 transformation
using BrF3. J. Org. Chem. 59: 2918.
7.
S. Rozen, A. Bar-Haim and E. Mishani (1994). Fluorination of nitro compounds with
acetyl hypofluorite. J. Org. Chem. 59: 6717.
8.
S. Rozen, E. Mishani (1994). A novel method for converting aromatic acids into
trifluoromethyl derivatives using BrF3. J. Chem. Soc. Chem. Commun. 2081.
9.
E. Mishani, C. S. Dence, T. J. McCarthy and M. J. Welch (1995). A study of trifluoro toluenes mediated [18F] fluoro - for - nitro exchange. A useful intermediate in
Eyal Mishani, Monday, November 04, 2013
-5-
the synthesis of highly fluorinated radiopharmaceuticals. J. Labl. Comp. Radiopharm.
37: S575-7.
10.
C. S. Dence, E. Mishani, T. J. McCarthy, M. J. Welch (1995).
microwave cavity for the synthesis of PET radiopharmaceuticals.
Radiopharm. 37: S115-6.
11.
S. Rozen, Y. Bareket, I. Ben-David and E. Mishani (1995). The impact of F2 on organic
chemistry. J. Labl. Comp. Radiopharm. 37: S641-3.
12.
E. Mishani, C. S. Dence, T. J. McCarthy and M. J. Welch (1996). Formation of
phenylpiperazines by a novel alumina supported bis-alkylation. Tet. Lett. 37: 319-322.
13.
E. Mishani, R. M. Brodbeck, J. E. Krause, C. S. Dence, T. J. McCarthy and M. J. Welch
(1997). Synthesis and evaluation of A fluorine-18 labeled NK-1 antagonist. J. Labl.
Comp. Radiopharm. 40: S653–655.
14.
E. Mishani, Michael E. Cristel, Carmen S. Dence, Timothy J. McCarthy, Michael J.
Welch (1997). Application of a novel phenylpiperazine formation reaction to the
radiosynthesis of 18FTFMPP, a potent serotonin agonist. J. Nucl. Med. Biol. 24: 269273.
15.
I. Ben-David, E. Mishani, S. Rozen (1998). tert-Butyl Hypofluorite - an electrophilic
tert-butoxylation agent. J. Org. Chem. 63: 4632.
16.
E. Mishani, N. Lifshits, A. Osavistky , J. Kaufman, N. Ankry, N. Tal, R. Chisin (1999)
.Radiation levels in cyclotron-radiochemistry facility measured by a novel comprehensive
computerized monitoring system. Nucl. Instr. Meth. Phys. Res. A, 425: 332-342.
17.
E. Mishani, T. A. Bonasera, Y. Rozen, G. Ortu, A. Gazit, A. Levitzki (1999).
Fluorinated EGFR-TK inhibitor-based tracers for PET. J. Labl. Comp. Radiopharm. 42:
S27-29.
18.
I. Ben David , D. Rechavi, E. Mishani , S. Rozen (1999). A Novel synthesis of
trifluoromethyl ethers via xanthates, utilizing BrF3. J. Fluorine Chem. 97: 75-78.
19.
M. Klein, N. Freedman, E. Mishani, Z. Gimon, M. Lotem, R. Chisin (2000). PET and
lymphoscintigraphic evaluation of malignant melanomas. Nuklear Medizin, 39: 56-61.
20.
M. Bocher, E. Mishani (2000). The contribution of Positron Emission TomographyPET to patient management in oncology. J. of the Israel Medical Association. 139: 6467.
21.
T. A. Bonasera, G. Ortu, Y. Rozen, R. Krais, N. M.T. Freedman, R. Chisin, A. Gazit, A.
Levitzki and E. Mishani (2001). Potential 18F-labeled biomarkers for Epidermal
Growth Factor Receptor Tyrosine Kinase. J. Nucl. Med. Biol. 28: 359-37.
22.
E. Mishani, I. Ben David, Y. Rozen, G. Ortu, A. Levitzki (2001). Carbon-11 labeled
irreversible inhibitors for mapping Epidermal Growth Factor Receptor Tyrosine Kinase
(EGFR-TK). J. Labl. Comp. Radiopharm. 44: S94-96.
23.
E. Mishani, I. Ben David (2001). [C-11] Acryloyl chloride- a fully automated
preparation and reaction with model amine. J. Labl. Comp. Radiopharm. 44: S475-476.
Evaluation of a
J. Labl. Comp.
Eyal Mishani, Monday, November 04, 2013
-6-
24.
E. Mishani, I. Ben-David, Y. Rozen, D. Laki, M. Bocher, R. Chisin (2001). [C11]Choline - automated preparation and clinical utilization. J. Labl. Comp. Radiopharm.
44: S379-381.
25.
M. Bocher, R. Chisin, Y. Parag, N. Freedman, Y. Meir, H. Lester, E. Mishani, O. Bone
(2001). Cerebral activation associated with sexual arousal in response to a pronographic
clip: A [O-15]water PET Study in heterosexual men. Neuroimage, 14: 105-117.
26.
G. Ortu, I. Ben-David, Y. Rozen, A. Levitzki, E. Mishani (2001). Biological evaluation
of a novel C-11 labelled irreversible EGFRTK inhibitor. Quar. J. Nucl. Med. 45: S7.
27.
E. Mishani, I. Ben-David, Y. Rozen (2002). Improved method for the quality
assurance of [C-11]choline. J. Nucl. Med. Biol. 29: 359-362.
28.
G. Ortu, I. Ben-David, Y. Rozen, N. M. Freedman, R. Chisin, A. Levitzki, E. Mishani
(2002). In-vitro and In-vivo investigation of an irreversible labeled EGFR inhibitor
(ML03) and its potential as PET biomarker in cancer and feasibility as an anticancer
drug. Int. J. of Cancer, 101: 360-37.
29.
I. Ben-David, Y. Rozen, G. Ortu, E. Mishani (2003). Radiosynthesis of ML03, a novel
positron emission tomography biomarker for targeting epidermal growth factor receptor
via the labeling synthon: [C-11]Acryloyl chloride. Appl. Rad. Isotp. 58: 209-217.
30.
E. Even-Sapir, U. Metser, G. Flusser, L. Zuriel, Y. Kollender, H. Lerman, G. Lievshitz,
I. Ron, E. Mishani (2004). Assessment of malignant skeletal disease: Initial
experience with 18F-Fluoride PET/CT and comparison between 18F-Fluoride PET and
18F-Fluoride PET/CT. J. Nuc. Med. 45: 272-278.
31.
E. Mishani, G. Abourbeh, Y. Rozen, O. Jacobson, D. Laky, I. Ben David, A. Levitzki,
M. Shaul (2004). Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular
imaging of EGFR-positive tumors. J. Nucl. Med. Biol. 31: 469-476.
32.
M. Shaul, G. Abourbeh, O. Jacobson, Y. Rozen, D. Laky, A. Levitzki, E. Mishani
(2004). Novel Iodine-124 labeled EGFR inhibitors as potential PET agents for
molecular imaging in cancer. Bioorg. Med. Chem. 12: 3421-3429.
33.
Y. Barda, N. Cohen, V. Lev, N. Ben-Aroya, Y. Koch, E. Mishani, M. Fridkin, C. Gilon
(2004). Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential
SPECT molecular imaging agent in cancer. J. Nucl. Med. Biol. 31: 921-933.
34.
O. Jacobson, Y. Bechor, A. Icar, N. Novak, A. Birman, H. Marom, L. Fadeeva, E.
Golan, I. Leibovitch, M. Gutman, E. Even-Sapir, R. Chisin, M. Gozin, E. Mishani
(2005). Prostate cancer PET bioprobes: synthesis of [18F]-Radiolabeled
hydroxyflutamide derivatives. Bioorg. Med. Chem. 13: 6195-6205.
35.
N. M. T Freedman, E. Mishani, Y. Krausz, J. Weininger, H. Lester, E. Blaugrund, D.
Ehrlich, R. Chisin (2005). In-vivo measurement of brain Monoamine Oxidase B
(MAO-B) occupancy by Rasagiline, using 11C-L-Deprenyl and Positron Emission
Tomography (PET). J. Nuc. Med. 46: 1618-1624. 35.
Eyal Mishani, Monday, November 04, 2013
-7-
36.
E. Mishani, G. Abourbeh, O. Jacobson , M. Shaul, R. Ben-Daniel , S. Dissoki, Y.
Rozen, A. Levitzki (2005). High affinity EGFR irreversible inhibitors with diminished
chemical reactivities as PET- imaging agent candidates of EGFR over-expressing
tumors. J. Med. Chem. 48: 5337-5348.
37.
O. N. Gofrit, E. Mishani, M. Orevi, M. Klein, N. Freedman, D. Pode, A. Shapiro, R.
Katz, E. Libson, R. Chisin (2006). Contribution of 11C-Choline PET/CT to
preoperative staging of patients with advanced Transitional Cell Carcinoma. J. Urol.
17: 940-944.
38.
E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, I. Leibovitch (2006).
The detection of bone metastases by 99mTC-MDP planar bone scintigraphy, single and
multi-field-of-views SPECT, 18F-fluoride PET and 18F-fluoride PET -CT. Prospective
study in 44 patients with high risk prostate cancer. J. Nuc. Med. 47: 287-297.
39.
O. Wald, I. D. Weiss, H. Wald, H. Shoham, Y. Bar-Shavit, K. Beyder, E. Galun, L.
Weiss, L. Flaishon , I. Shachar, A. Nagler, B. Lu, C. Gerard, J.L. Gao, E. Mishani, J.
Farber, and A. Peled (2006). IFN- acts on T cells to induce NK cell mobilization and
accumulation in target organs. J. Immunol. 176 (8): 4716-29.
40.
S. Dissoki, D. Laky, E. Mishani (2006). Fluorine-18 labeling of ML04 – presently the
most promising irreversible inhibitor candidate for visualization of EGFR in cancer. J.
Labl. Comp. Radiopharm. 49 (6): 533-543.
41.
O. Jacobson, D. Laky, K. E. Carlson, S. Elgavish, M. Gozin, E. Even-Sapir, I.
Leibovitc, M. Gutman, R. Chisin, J. A. Katzenellenbogen and E. Mishani (2006).
Chiral dimethylamine flutamide derivatives - modeling, synthesis, androgen receptor
affinities, and carbon-11 labeling. J. Nucl. Med. Biol. 33: 695-704.
42.
A. Levitzki and E. Mishani (2006). Tyrphostins and other tyrosine kinase inhibitors.
Annu. Rev. Biochem. 75: 93-109.
43.
A. Shushan, H. Ben-Bassat, E. Mishani, N. Laufer, BY. Klein, and N. Rojansky
(2007). Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein
tyrosine kinase inhibitor TKS050. Fertil. Steril. 87 (1): 127-135.
44.
G. Abourbeh , S. Dissoki, O. Jacobson, A. Litchi, R. Ben Daniel, D. Laki, A. Levitzki
and E. Mishani (2007). Evaluation of radiolabeled ML04, a putative irreversible
inhibitor of the Epidermal Growth Factor receptor, as bioprobe for PET imaging of
EGFR overexpressing tumors. J. Nucl. Med. Biol. 34: 55-70.
45.
S. Dissoki, Y. Aviv, D. Laky, G. Abourbeh, A. Levitzki and E. Mishani (2007). The
effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline6-yl]-amide moiety – an EGFR putative irreversible inhibitor. Appl. Rad. Isotp. 65:
1140-1151.
46.
E. Even-Sapir, E. Mishani, G. Flusser, U. Metser (2007). 18F-Fluoride Positron
Emission Tomography and Positron Emission Tomography/Computed Tomography.
Semin. Nucl. Med. 37 (6): 462-469.
Eyal Mishani, Monday, November 04, 2013
-8-
47.
E. Mishani, G. Abourbeh (2007). Cancer molecular imaging: Radionuclide-Based
biomarkers of the Epidermal Growth Factor Receptor (EGFR). Curr. Top. Med. Chem.
7 (18): 1755-1772.
48.
O. Jacobson, E. Mishani (2008). [11C]-Dimethylamine as a labeling agent for PET
biomarkers. Appl. Rad. Isotp. 66: 188-193.
49.
A Bar-Haim Erez , N. Freedman , N. Katz , O. Abramsky , E. Mishani, R. Chisin
(2008). Neural mechanism of visual attention in unilateral spatial neglect following
stroke: A preliminary PET study. Israeli Journal of Occupational Therapy. 17(1), E322.
50.
O. Ilovich, O. Jacobson, Y. Aviv (S), A. Litchi, R. Chisin, E. Mishani. (2008).
Formation of fluorine-18 labeled diaryl ureas-labeled VEGFR-2/PDGFR dual inhibitors
as molecular imaging agents for angiogenesis. Bioorg. Med. Chem. 16: 4242-4251.
51.
R. Ben Daniel, W. Deuther-Conrad, M. Scheunemann, J. Steinbach, P. Brust, E.
Mishani. (2008). Carbon-11 labeled indolylpropylamine analog as a new potential PET
agent for imaging of the serotonin transporter. Bioorg. Med. Chem. 16: 6364-6370.
52.
E. Mishani, G. Abourbeh, M. Eiblmaier and C. J. Anderson (2008). Imaging of the
EGFR and EGFR tyrosine kinase overexpression in tumors. Curr. Pharm. Design,14
(28): 2983-2998
53.
S. Dissoki, R. Eshet, H. Billauer, E. Mishani. (2009). Modified PEGanilinoquinazoline derivatives as potential EGFR PET agents. J. Labl. Comp.
Radiopharm. 52: 41-52.
54.
O. Ilovich, O. Åberg, B. Långström and E. Mishani. (2009). Rhodium-mediated
[11C]Carbonylation: A library of N-Phenyl-N’-{4-(4-quinolyloxy)-phenyl}-[11C]-urea
derivatives as potential PET angiogenic probes. J. Labl. Comp. Radiopharm. 52: 151157.
55.
I. Ruvinsky , M. Katz, A. Dreazen, Y. Gielchinsky, A. Saada , N. Freedman, E.
Mishani, G. Zimmerman, J. Kasir, O. Meyuhas. (2009). Mice deficient in ribosomal
protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect
and energy deficit. PLoS ONE, 2009 May 19;4(5):e5618.
56.
E. Afergan, H. Epstein, N. Koroukhov, M. Klein, A. Litchi, E. Mishani, G. Golomb.
(2009). Biodistribution and Imaging studies of 67Ga-Labeled Liposomes in Rabbits with
a Vascular Injury. J. Drug Deliv. Sci. Tec. 19: 263-268.
57.
E. Mishani, A. Hagooly (2009). Strategies for molecular imaging of Epidermal Growth
Factor Receptor Tyrosine Kinase in cancer. J. Nuc. Med. 50 (8):1199-1202
58.
MA. Pantaleo, E. Mishani, C. Nanni, L. Landuzzi , S. Boschi, G. Nicoletti, S.
Dissoki, P. Paterini, PP. Piccaluga , F. Lodi, PL. Lollini , S. Fanti and G. Biasco.
Eyal Mishani, Monday, November 04, 2013
-9-
(2010). Evaluation of modified PEG-anilinoquinazoline derivatives as potential
agents for EGFR imaging in cancer by small animal PET. Mol. Imaging Biol. 12 (6):
616-625.
59.
O. Ilovich, H. Billauer, S. Dotan and E. Mishani. (2010). Labeled 3-aryl-4indolylmaleimide derivatives and their potential as angiogenic PET biomarkers.
Bioorg. Med. Chem. 18 (2): 612-620.
60.
O. Cohen, E. Mishani, S. Rozen. (2010). From carboxylic acids to the
trifluoromethyl group using BrF3. Tetrahedron, 66: 3579–3582.
61.
O. Ilovich, H. Billauer, S. Dotan, N. M.T. Freedman, M. Bocher, and E. Mishani
(PI). (2011). Novel and simple carbon-11 labeled ammonium salts as PET agents for
myocardial perfusion imaging. Mol. Imaging Biol. 13: 128-139.
62.
Y. Krausz , N. Freedman, R. Rubinstein, E. Lavie, M. Orevi, S. Tshori , A.Salmon , B.
Glaser, R. Chisin, E. Mishani, DJ. Gross . (2011). 68Ga-DOTA-NOC PET/CT imaging
of neuroendocrine tumors: comparison with 111In-DTPA-Octreotide (OctreoScan®).
Mol. Imaging Biol. 13: 583-593.
63.
F. Wolfhagen Sand, A. Hornblad , JK. Johansson, C. Loren, J. Edsbagge, J.
Magenheim, O. Ilovich, E. Mishani , Y. Dor, U. Ahlgren , H. Semb . (2011). Growthlimiting role of endothelial cells in endoderm development. Dev. Biol. 352: 267-277.
64.
A. Lazarus, PM. Del-Moral, O. Ilovich, E. Mishani, D. Warburton, and E. Keshet.
(2011). A perfusion-Independent role of blood vessels in patterning branching
stereotypy of mouse lung airway. Development, 138: 2359-2368.
65.
S. Dissoki, A. Hagooly, S. Elmachily, E. Mishani (2011). Labelling approaches for the
GE11 peptide - an EGFR biomarker. J. Labl. Comp. Radiopharm. 54: 693-701.
66.
J. Magenheim, O. Ilovich, A. Lazarus, A. Kolchendler, O. Ziv, R. Werman, A. Hija, O.
Cleaver, E. Mishani, E. Keshet, Y. Dor. (2011). Blood vessels restrain bracnching,
differentiation and growth. Development, 138: 4743-4752.
67.
A. Gruzman, A. Elgart, O. Viskind, H. Billauer, S. Dotan , G. Cohen , E. Mishani, A.
Hoffman, E. Cerasi , S. Sasson (2012). Antihyperglycaemic activity of a lipophilic
pentose derivative intype-1 and type-2 diabetic mice. J. Cell. Mol. Med. 16: 594-604.
68.
Y. Krausz, R. Rubinstein , L. Appelbaum, E. Mishani, M. Orevi , M. Fraenkel, S.
Tshori, B. Glaser, M. Bocher, A. Salmon, R. Chisin , DJ. Gross , N. Freedman . (2012).
Ga-68 DOTA-NOC uptake in the pancreas: Pathological and physiological patterns.
Clin. Nucl. Med. 37 (1): 57-62.
69.
O. Ilovich, G. Abourbeh, M. Bocher, N. Freedman, H. Billauer, S. Dotan, H. D.
Danenberg and E. Mishani. (2012). Structure-activity relationship and preclinical
Eyal Mishani, Monday, November 04, 2013
- 10 -
evaluation of carbon-11-labeled ammonium salts as PET-myocardial perfusion imaging
agents. Mol. Imaging Biol. 14: 625-636.
70.
M. Orevi, M. Klein, E. Mishani, R. Chisin, N. Freedman, O. N. Gofrit. (2012). C-11
acetate PET/CT in bladder urothelial carcinoma: Intraindividual comparison with C-11
choline. Clin. Nucl. Med. 37 (4): e67-72.
71.
G. Abourbeh , A. Shir, E. Mishani, M. Ogris, W. Rödl, E. Wagner and A. Levitzki.
(2012). PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life, 64
(4): 324-330.
72.
AL. Kesner, G. Abourbeh, E. Mishani, R. Chisin, S. Tshori and N. Freedman. (2013).
Gating, enhanced gating, and beyond: information utilization strategies for motion
management, applied to preclinical PET. Eur. J. Nucl. Med. Mol. I. Res. 3 (1): 1-15.
73.
V. Kepe, M.C. Moghbel, B. Langstrom, H. Aaidi, H. V. Vinters, S.C. Huang, N.
Satyamurthy, D. Doudet, E. Mishani, R. M. Cohen, P. F. Hoilund-Carlsen, A. Alavi, J.
R. Barrio. (2013). Amyloid-β Positron Emission Tomography Imaging Probes: A
Critical Review. J Alzheimers Dis. 36 (4):613-631.
74.
Jacobson O., Abourbeh G., Tsvirkun D., Mishani E. (2013). Rat Imaging and In
Vivo Stability Studies using [11C]-Dimethyl-Diphenyl Ammonium, a Candidate Agent
for PET-Myocardial Perfusion Imaging. J. Nucl. Med. Biol. In Press.
Patents
1.
E. Mishani, T. A. Bonasera, Y. Rozen, G. Ortu, A. Gazit, A. Levitzki. Novel
Epidermal Growth Factor Receptor-Kinase Binding Compounds for Positron Emission
Tomography.
U.S. Patent No. 6,126,917 (2000).
2.
E. Mishani, I. Ben David, Y. Rozen, G. Ortu, A. Levitzki, Radiolabeled inhibitors for
Epidermal Growth Factor Receptor Tyrosine Kinase and their use in radioimaging and
radiotherapy.
U.S. Patent No. 6,562,319 (2003).
Eyal Mishani, Monday, November 04, 2013
4.
- 11 -
S. Dissoki, G. Abourbeh, A. Levitzki, E. Mishani. Labeled EGFR irreversible biomarkers:
Anilinoquinazoline-7-[F-18]-PEG derivatives.
U.S. patent No. 8,461,166 (2006).
5.
E. Mishani, O. Jacobson.
11
C AND
18
F- labeled Androgen-Receptor (AR) ligands for
use in the treatment and diagnosis of AR-related pathologies.
Applied to U.S. patent (2006).
6.
E. Mishani, Y. Rozen, G. Abourbeh, A. Levitzki. Novel EGFR-TK irreversible
inhibitors for cancer therapy, radiotherapy and diagnosis.
U.S. Patent No. 7,172,749 (2007).
7.
E. Mishani, H. Billauer, G. Abourbeh, S. Dotan, N. M.T. Freedman, H. Danenberg, M.
Bocher. Ammonium salt for myocardial perfusion imaging.
Applied to U.S. patent (2011).
Invited lectures.
1.
Alkylhypofluorite and electrophilic fluorination, Corporate science and technology
center, Air Products and Chemicals, USA, 1996.
2.
Positron Emission Tomography - overview, Nuclear Research Center – Sorek, Israel,
1998.
3.
Positron Emission Tomography - overview, Nuclear Research Center – Negev, Israel,
1998.
4.
PET-Oncology, [C-11]Choline and EGFR labeled inhibitors, Tel Aviv University,
School of Chemistry, 2001.
5.
The inter-phase, nuclear physics-nuclear medicine. Mini-seminar, The Israeli
pharmacist organization, Health Ministry. Sorasky Medical Center, Tel Aviv, 2003.
6.
Direct labeling of Tyrosine Kinase ligands. Work-shop; Modern imaging technology,
Annual Conference of the Society of Nuclear Medicine, New Orleans, USA, 2003.
Invited lecture.
7.
PET molecular imaging of angiogenesis and gene therapy. Rambam Hospital &
Rapaport Institute, Haifa, Israel, 2004.
Eyal Mishani, Monday, November 04, 2013
- 12 -
8.
Labeled molecular imaging agents of the EGFR-TK for specific in-vivo diagnostic
and, image guided treatment of cancer. Bioorganic Chemistry. The 69th Meeting of the
Israel Chemical Society, Tel Aviv, Israel, 2004.
9.
PET radiopharmaceuticals for oncology. Rambam Hospital & Rapaport Institute,
Haifa, Israel, 2004.
10. Animal-PET and Micro-PET molecular imaging. Imaging in laboratory animalsexperimental approaches and techniques. Hebrew University/Hadassah Hospital. The
Authority for Animal Facilities, Israel, 2005.
11. Visualizing EGFR in cancer. Azienda Ospedaliera S.Orsola-Malpighi University
Hospital. Bologna, Italy. 2005
12. Receptor based molecular imaging in oncology. New trends in molecular imaging and
nuclear medicine. Annual Conference at the University of Bologna Italy. 2006
13. PET imaging bioprobes in oncology: design, labeling and preclinical studies.
Department of Biological Regulation, Weizmann Institute of Science, Israel 2007.
14. PET bioprobes for molecular imaging. Hybrid imaging (PET/CT) symposium, Philips.
Israel 2007.
15. Personalized medicine: Image guided treatment. Israel Medical Convention,
Jerusalem, Israel 2007.
16. PET radiopharmaceuticals production and clinical application. Soreq Nuclear
research center, Israel, 2008.
17. Development of radiolabeled inhibitors of EGFR and VEGFR Tyrosine Kinases as
PET agents. "Molecular imaging for better diagnosis and management of diseases"
Bayer Healthcare, Bayer Schering pharma, Life Sciences Workshop Series, Berlin,
Germany, 2008.
18. PET isotopes and radiopharmaceuticals: production and clinical application.
Symposium honoring the 90th birthday of Prof. Israel Dostrovsky; Outward Bound:
From nuclear chemistry to solar neutrinos. Weizmann Institute of Science, Israel
2008.
19. Novel PET tracers for imaging of cancer patients. Annual Conference of the
European Organization for Research and Treatment of Cancer, Radiation Oncology
Group (EORTC-ROG), Haifa, Israel, 2009.
20. PET Biomarkers for molecular imaging. BIT’s 1st Annual Tera-congress of molmed,
Shanghai China, 2010.
21. PET molecular imaging agents – labeled magic bullets. Rambam Hospital, Haifa,
Israel, 2010.
22. PET molecular imaging agents in oncology and cardiology, Albert Einstein Hospital,
Sao Paulo, Brazil. 2011.
Eyal Mishani, Monday, November 04, 2013
- 13 -
23. Strategies for molecular imaging of Epidermal Growth Factor Receptor Tyrosine
Kinase in cancer. New Frontiers in Molecular Imaging and Therapy Conference,
National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand.2011.
24. Tracers beyond FDG: New magic bullets. New Frontiers in Molecular Imaging and
Therapy Conference, National Cyclotron and PET Centre, Chulabhorn Hospital,
Bangkok, Thailand. 2011.
25. PET molecular imaging in oncology and cardiology, The Racah Inst. of Physics,
Hebrew University, Jerusalem, Israel.2012.
26. PET molecular imaging in oncology and cardiology, Tel Aviv University, School of
Chemistry, Tel Aviv, Israel. 2012.
27. Sustaining proliferative signaling, Imaging Sigmal transduction in Cancer, The 7th
ESMI Winter conference - Hot Topic in molecular Imaging: Imaging Hallmark of
Cancer, France, 2013.
28. PET molecular imaging in oncology and cardiology, Bar-Ilan University, School of
Chemistry, Tel Aviv, Israel. 2013.
29. PET MPI imaging agents, International Conference on Integrated Medical Imaging in
Cardiovascular Diseases (IMIC 2013). International Atomic Energy Agency, Vienna,
Austria. 2013.
30. The quality control Process of MPI Agents, International Conference on Integrated
Medical Imaging in Cardiovascular Diseases (IMIC 2013). International Atomic
Energy Agency, Vienna, Austria. 2013.